Introduction
Retinoids (analogues of vitamin A) are known to possess anticancer properties as well as provide useful pharmaceutical responses in the treatment of various other disorders and thus have received considerable scientific attention during the past 2 decades. 1 Retinoids exhibit their therapeutic properties, at least in part, by interaction with and activation of a specific group of nuclear receptors, termed retinoid receptors. 2 The retinoid receptors are divided into two distinct types, namely the retinoic acid receptors (RARs) 3 and the retinoid X receptors (RXRs). 4 For each type, three receptor subtypes, namely RARR, -, and -γ and RXRR, -, and -γ, have been identified, for a total of six retinoid receptors. These retinoid receptors belong to the hormone receptor superfamily, and, as a group, this family of proteins regulates the transcription of genes that control a variety of metabolic, developmental, and differentiation pathways. Because the misregulation of any one of these pathways could enhance carcinogenesis, the hormones, or compounds such as retinoids, may regulate these receptors and are therefore potentially chemopreventive agents. 5 Naturally occurring retinoids trans-retinoic acid (1) and 9-cis-retinoic acid (2) are endogenous ligands for the retinoid receptors and have demonstrated significant anticancer properties, as has 13-cis-retinoic acid (3). 6 Some synthetic successor retinoids, such as arotinoid TTNPB (4) and the clinically employed Etretinate (5) , have also shown potent anticarcinogenic characteristics. 6 However, all of these retinoids have found limited application due to teratogenicity 7 and/or toxic manifestations such as diarrhea, hair loss, nausea, and headaches. 7, 8 Thus, the study of heteroarotinoids originated 9,10 as an attempt to mimic the anticarcinogenic action of retinoids, while at the same time reducing unwanted side effects. In fact, several heteroarotinoids have demonstrated reduced toxicity compared to 1 and 4 9e and, in some examples, exhibited greater anticancer activity than selected natural retinoids. 9,10 Consequently, heteroarotinoids are currently under extensive investigation for the potential treatment of a variety of disorders. 9, 10 Heteroarotinoids such as 6-10 constitute a class of synthetic retinoids 9,10 that structurally resemble arotinoids in that at least one aryl moiety is present within the molecular structure. However, heteroarotinoids contain an aryl-fused heterocyclic ring as a modification, and several studies have shown that some heteroarotinoids demonstrate promising inhibition of various cancers as well as reduced toxicity. 2c,9,10 Recent investigations of heteroarotinoids focused on structures containing a two-atom "linker" group (two atom moiety connecting the two aryl rings), 9 such as an amide (8) , 9b ester (9), 9c or N-methoxyamide (10) 9b functionality, among others. 9e It logically followed that synthesis and study of heteroarotinoids containing three-atom or even four-atom linkers, similar to those in the two-atom linker structures, would be worthwhile. Although a search of the literature revealed some retinoids with three-or more-atom linkers, [11] [12] [13] structures with only a few types of three-atom linker groups, such as chalcone (11) , propenol (12) , or R-hydroxyamide groups (13), 12 have been reported. Only one retinoid (14) containing a 1,4-diketone group as a four-atom linker was found. 11b The rationale for our present work is based upon the above citations and on the following observations. Utilizing a computer simulation program which, when modified slightly, allowed the creation of flexible ligand/ receptor, or combinations thereof, it was discovered that the flexible ligands were at a slightly lower energy than the fixed ligands based upon X-ray diffraction studies of RARγ∠t-RA where both ligand and receptor were in rigid forms. 9c Moreover, a urea or thiourea linker between the aryl rings introduces marked flexibility in the ligand and provides H-bonding capablility in a strategic location within the molecule. Certain studies had suggested 12, 13 that the presence of a three-atom linker may increase specificity for the RARs. Others demonstrated that a linker with an attached, nonbulky functionality capable of hydrogen bonding via proton donation (such as via an OH) enhanced RARγ selectivity. 12, 14 By constructing an agent possessing a semiflexible, three-atom linker with self-capability of hydrogen bonding through proton donation, it was reasoned that possibly a higher RARγ specificity would be produced, thus further increasing the efficacy of such retinoids. Furthermore, due to a high expression of RARγ in both skin 15 and urogenital tissues, 16 such an agent could be useful for the specific treatment of disorders such as melanoma or vulvarian carcinomas.
We now report the synthesis and biological activity of sulfur-containing heteroarotinoids 15a-15h with thiourea and urea linkers between the aryl rings. No heteroarotinoids with this type of linker have been reported. 11a Interestingly, the heteroarotinoids described did not activate retinoid receptors in two assays. However, the sulfur-containing heteroarotinoid systems 15a-h (Tables 1 and 2 ) demonstrated marked inhibitory ability for growth of ovarian cancer cell lines Caov-3, OVCAR-3, SK-OV-3, ICU-101, and 222. The EC 50 values of the compounds were compared to that of 4-hydroxyphenylretinamide (4-HPR), a clinically used retinoid, 17 which has been shown to induce reactive oxygen species (ROS). Growth inhibition by heteroarotinoids 15a was associated with cell loss and induction of ROS.
Results and Discussion
Chemistry. Due to the reduced toxicity and cancer inhibition exhibited by some reported sulfur heteroarotinoids, 2c,9a,9e a heterocyclic ring containing a gem-dimethyl group adjacent to a sulfur atom was chosen as part of 18 to afford the 6-isomer 17 in a modest yield (26%) with many other products being formed. However, in this case only 1 equiv of the nitrating agent was used, as compared to 2 equiv in the reported procedure, 9b and with little loss in yield (27% being reported previously 9b ).
Reduction of the nitro group in 17 was accomplished using iron/acetic acid 19 in refluxing EtOH to yield amine 18 (40%). Although a previous method 9b recorded a yield of 50% for amine 18 from the reduction of the nitro group in 17, it required the use of a very large excess of expensive TiCl 3 /HCl. In addition, the reaction workup was complicated and required the handling of titanium salts. In contrast, the iron/acetic acid approach is lowcost and the workup is relatively simple. It seemed reasonable to prepare analogues of 15a, 15b, and 15d possessing a methyl group attached to the fused ring system at the C7 position, a situation which could assist in determining more precisely the ligandreceptor interactions within the hydrophobic region of the receptor's ligand-binding pocket (LBP). 9b,c,20
Heteroarotinoid analogues 15f-h were envisioned to be accessible from unknown amine 24. Thus, the conversions of 19 f 20 f 21 f 22 f 23 f 24 (Scheme 1) was implemented and provided 24, which was then used to generate the targets 15a-h ( Table 1 ). The sequence utilized 3-methylthiophenol in a Michael addition to mesityl oxide and yielded ketone 20 (87%). Treatment of ketone 20 with excess MeMgBr gave alcohol 21 (84%). Dehydration-cyclization of 21 was then accomplished by the action of AlCl 3 in CS 2 to afford thiochroman 22 (93%). Nitration of thiochroman 22 was achieved using HNO 3 /Ac 2 O 18 to afford the 6-isomer 23 in a modest yield (26%), with several byproducts being formed, including some via oxidation of the sulfur atom. Reduction of the nitro group in 23 occurred with Fe/ AcOH 18 in refluxing EtOH to yield amine 24 (45%).
The thiourea or urea group (Table 1) was chosen as a three-atom linker due to its somewhat flexible nature, which might allow a good fit into the RARs and therefore enhance activation. Moreover, a thiourea or urea function provides two -NH-groups capable of hydrogen bonding with the receptor, thus possibly improving RARγ selectivity. To generate the desired heteroarotinoids 15a-h possessing urea linking groups, the conversions of 18 f 15a-e and 24 f 15f-h (Table  1) were performed. Amine 18 (or 24) was coupled with isocyanates and/or isothiocyanates in dry THF. The crude products were recrystallized from appropriate solvent systems to afford the desired compound with generally good yields.
Biological Activity
Cisplatin is used as the current standard of care chemotherapy administered to patients with ovarian cancer. Compounds 15a-h (Table 2) were evaluated for their ability to inhibit the growth of three ovarian carcinoma cell lines, Caov-3, OVCAR-4-, and SK-OV-3, a The potency difference is the concentration that exerts half-maximal activity (EC50 value) derived from a graph of percent growth inhibition versus concentration using GraphPad Software. b The efficacy is the growth inhibition activity of the compound at 10 µM concentration relative to the maximum activity observed for 4-HPR with the respective cell line. The maximal growth inhibition activity of 10 µM 4-HPR (25) was 61.97% for Caov-3, 43.1% for OVCAR-3, and 64.9% for SK-OV-3. The results represent the average and standard error of three experiments performed in triplicate.
which vary in their sensitivities to retinoids and cisplatin. The OVCAR-3 is cisplatin resistant, while Caov-3 and SK-OV-3 are cisplatin-sensitive. The SK-OV-3 line is resistant to classical retinoid receptor-active retinoids, while Caov-3 and OVCAR-3 are sensitive to these retinoids. The activities of the heteroarotinoids were compared to that of the well-known retinoid 4-HPR (25) , 17 which has demonstrated chemoprevention activity against ovarian cancer in clinical trials. The potencies and efficacies derived from the growth inhibition curves are summarized in Table 2 .
All three cell lines were growth inhibited by all of the heteroarotinoids tested, with EC 50 values in the micromolar range, similar to 4-HPR (25) . Interestingly, the cisplatin-resistant OVCAR-3 cell line and retinoic acidresistant SK-OV-3 cell line were sensitive to these compounds. The individual substitutions induced slight alterations in the efficacy in a cell-dependent manner. Overall, compound 15c, containing an NO 2 group, exhibited the highest activities against all cell lines tested in terms of strong efficacies and very good potencies. Regarding potencies, 15c was actually as good or more potent than the clinical agent 4-HPR (25) .
Given the potential clinical application of these compounds for prevention and treatment of ovarian cancer, it was important to determine if the agents were toxic to normal cells and to pre-neoplastic lesions that had not yet become cancerous. To evaluate the therapeutic ratios, the growth inhibition activities of heteroarotinoids 15a-c, 9-cis-retinoic acid (9-c-RA, 2), and 4-HPR (25) in primary cultures derived from normal endometrial cells were compared to the activities in cultures of the OVCAR-3 ovarian cancer cell line, a borderline ovarian tumor (O1), and a benign ovarian tumor (O3) (Figure 1 ). The 9-cis-retinoic acid (9-c-RA, 2) did not inhibit growth of any of these cultures. Heteroarotinoids 15a-c and 4-HPR (25) exhibited strong growth inhibition against the ovarian cancer cell line and weak inhibition of the normal endometrial cells, demonstrating good therapeutic ratios. The heteroarotinoids exhibited strong growth inhibition against the borderline tumor, demonstrating potential to prevent progression of pre-neoplastic lesions to cancer, while 4-HPR (25) exhibited weak activity against the borderline culture. Although benign ovarian cysts rarely progress to cancer, they are often removed surgically due to the deleterious effects of an increasing size. Heteroarotinoid 15c exhibited the most potent growth inhibition activity (4 µM) against the benign ovarian culture.
The strong growth inhibition activity of the heteroarotinoids suggests that cell loss may be due to induction of apoptosis. In two related studies 9a,21 with 15a-c (previously labeled SHetA4, SHetA3, and SHetA2, respectively), 9a,21 it was demonstrated that these agents induced apoptosis in ovarian and head/neck cancer cell lines. To further evaluate the mechanism of growth inhibition in ovarian cancer, the effects of 15c at two different concentrations (5 and 10 µM) were evaluated on two additional ovarian cell lines (UCI 101 and 222). Within 24 h of treatment, the growth of both cell lines were completely blocked by 15c at both concentrations (Figure 2) . Within 48 h, cell loss was apparent at the 10 µM concentration (Figure 2 ). To further investigate the mechanism of this cell loss, ROS was measured in both cell lines after treatment with 15c over a range of concentrations for 24 h. At 1 µM concentration, 15c did not induce ROS, while at 5 and 10 µM concentrations of 15c (SHetA2), ROS was induced in a dose-response manner (Figure 3 ).
Conclusions
Chemoprevention activity by 4-HPR (25) is thought to induce apoptosis through retinoic acid-receptorindependent mechanisms only at concentrations above those achieved in clinical chemoprevention trials. 22 At concentrations <1 µM, however, 25 appears to behave similarly to classical retinoids by inducing differentiation through a receptor-dependent mechanism. 17, 22 Since 15a-h did not exhibit RARγ receptor activation in the assays employed, it is conceivable that these heteroarotinoids may act by way of a different receptor or by an independent pathway. 17, 22 The efficacy of these heteroarotinoids against ovarian cancer cell lines which are resistant to standard cisplatin chemotherapy and to trans-retinoic acid (1) suggests that these agents may possess a unique mode of action. This is consistent with the lack of direct activation of the retinoic acid receptors. The present study demonstrates that the growth inhibition by 15a-c is due to cell loss. In a related study, 9a it was shown that cell loss in the OVCAR-3 ovarian cancer cell line was due to induction of apoptosis. Since 15c exhibited the highest degree of growth inhibition in a variety of cell lines, this compound was evaluated in more detail for the mechanism of apoptosis. In a study of head and neck cancer cell lines, specific inhibitors were used to demonstrate that the induction of apoptosis by 15c was mediated through induction of ROS, G2 cell cycle arrest, alterations in mitochondrial membrane permeability transition (MPT), release of cytochrome c from the mitochondria to the cytosol, and activation of caspase 3. 21 In addition, a specific antagonist of retinoic acid receptors was utilized to confirm that 15c induced apoptosis independent of the retinoic acid receptors. 21 The current study clearly demonstrates that ovarian cancer cell lines also generate ROS in response to treatment with heteroarotinoid 15c.
The differential effects of 15a-c on normal versus cancer cells observed in this study clearly show that such agents with urea and/or thiourea linkers have a favorable therapeutic ratio in that cancer and precancer cells were growth inhibited to much greater extents than normal or benign cells. This favorable therapeutic ratio was also observed in another study that illustrated that 15b and 15c inhibited the growth of OVCAR-3 xenograph tumors in an animal model to similar degrees as noted with 4-HPR (25) without any evidence of toxicity. 23 The lack of hypervitaminosis A toxicities of 15b and 15c in the animal model supports our observations that these compounds act independently of the retinoic acid receptors. 9a,23,24 In summary, we have developed procedures to obtain a variety of heteroarotinoids with a urea or thiourea linking group. The series of heteroarotinoids 15a-h contain the first such examples possessing flexible urea or thiourea groups as three-atom linkers. 11 The syntheses involved a coupling reaction of various isocyanates or isothiocyanates in THF with previously rare or unknown amines 18 and 24, respectively. The heteroarotinoids described herein effectively inhibit growth of a variety of ovarian cancer cell lines. Some of the agents have demonstrated anticancer activities and a therapeutic window comparable to that of the clinical agent 4-HPR (25) . The sensitivity of cisplatin-resistant OVCAR-3 cell lines suggests the potential use of these heteroarotinoids in preventing recurrence of ovarian cancer in patients who have received cisplatin chemotherapy. Otherbiologicaleffectsof15a-chaveappearedelsewhere. 9a Moreover, 15a and 15b act as antagonists of Mycobacterium bovis BCG, which suggests the agents inhibit mycolic acid synthesis (see the companion paper). 25 Results from the present work and related studies 9,21,23 demonstrate that this new class of heteroarotinoids induces apoptosis in cancer cells to a greater extent than in normal cells through a mechanism that is independent of retinoic acid receptor activation and involves the generation of ROS. 26 Compound 15c (labeled ShetA2 in the literature 9a ) is now in preclinical development for cancer prevention and treatment through the National Cancer Institutes (NCI) Rapid Access to Intervention Development (RAID) program. Thus, the present work provides a background for additional exploration of the structures of heteroarotinoids as anticancer agents.
Experimental Section
Commercial reagents and solvents were used as received unless otherwise noted. Anhydrous THF was obtained by distillation from a purple solution of sodium and benzophenone. All of the isocyanates and isothiocyanates were commercially available and were obtained from Lancaster Synthesis, Inc., Windham, NH. Unless otherwise indicated, all reactions were run under dry N 2 and all purification beyond recrystallization was done via flash chromatography, utilizing J. T. Baker flash chromatography silica gel packing, 40 µm particle size. Melting points were determined using a ThomasHoover melting point apparatus and were uncorrected. IR spectra were obtained using a Perkin-Elmer 2000 FT-IR spectrometer as films or KBr pellets. Unless stated otherwise, all 1 H and 13 C NMR spectra were performed using DCCl3 as the solvent and obtained using a Varian UNITY INOVA 400 BB NMR spectrometer operating at 399.99 and 100.01 MHz, respectively. Signals were referenced to TMS. Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, GA.
Although the intermediates and final products appeared to be relatively stable in light, precautions were taken to minimize exposure to any light source and to the atmosphere. In the purified state, all products were stored in the cold and dark without significant decomposition. Intermediates appeared to be similar in sensitivity and were treated likewise.
General Procedure for the Preparation of Heteroarotinoids 15a-h from Amine 18 or 24. To a solution of amine 18 or 24 (1.0 mmol) in dry THF (4.5 mL) at 0°C was added dropwise the desired isocyanate or isothiocyanate (1.02 mmol) in dry THF (5 mL) over 3 min. After the addition, the reaction mixture was allowed to warm to room temperature and then was stirred for 24 h. The solvent was evaporated, and the residue was recrystallized to give an analytically pure sample of the corresponding heteroarotinoid. (C24H30N2O2S2) C, H, N 2,2,4,4-Tetramethyl-6-nitrothiochroman (17). The following procedure gave a more pure sample of 17 over that reported. 9b To a solution of thiochroman 16 10a (15.00 g, 72.7 mmol) in freshly distilled Ac2O (14 mL) at -5°C (ice/salt) was added dropwise a mixture of cold, concentrated HNO3 (5.21 mL) and Ac2O (12.20 mL) over 10 min. After being stirred at -5°C for 90 min, the reaction mixture was poured into a solution of saturated, aqueous NaHCO3 (140 mL), and the resulting emulsion was extracted (H2CCl2; 3 × 83 mL). The combined organic extracts were washed with H2O (45 mL) and brine (45 mL) and were then dried (Na2SO4). Evaporation of the solvent gave a dark brown liquid, which was subjected to flash chromatography [hexanes:EtOAc (3:1)] to provide 17 9b 2,2,4,4-Tetramethyl-6-aminothiochroman (18). The following procedure gave a more pure sample of 18 compared to that reported. 9b A mixture of 17 9b (5.40 g, 21.5 mmol), iron powder (0.850 g, 15.2 mmol, Sigma-Aldrich Chemical Co.), glacial acetic acid (1.80 g, 30 mmol), and absolute EtOH (11 mL) was stirred at reflux for 12 h. The reaction was allowed to cool to room temperature and was poured into H 2O (45 mL), and the resulting emulsion was extracted with ether (2 × 40 mL) and HCCl3 (3 × 40 mL). The combined organic extracts were washed with H2O (3 × 40 mL), dried (Na2SO4), and concentrated to give a dark oil. This crude mixture was then dissolved in ether (30 mL), and the resulting solution was extracted with 2 N HCl (2 × 30 mL). The acid solution was neutralized with 40% Na 2CO3 (pH ∼8), and the resulting solution was extracted (ether; 2 × 30 mL). The organic extracts were dried (Na2SO4), and the solvent was evaporated to give amine 18 9b (0.370 g, 42%) as a tan oil which crystallized upon standing overnight in a freezer and was recrystallized (hexanes) to yield an off white solid: mp 58-60°C (lit. 9b mp 57-59°C). Spectral data for the product matched reported values, 9b and amine 18 was used immediately to prepare 15a-e.
Ethyl 4-{[N-(2,2,4,4-Tetramethylthiochroman-6-yl)-carbamoyl]amino}benzoate (15a

4-Methyl-4-(3-methylphenylthio)-2-pentanone (20).
To a solution of 3-methylthiophenol (19, 15 .00 g, 0.121 mol), mesityl oxide (11.42 g, 0.116 mol), and HCCl 3 (47 mL) at 0°C was added 0.7 mL of triethylamine. The cold bath was removed after the addition (0.25 h) of triethylamine, and the solution was stirred (room temperature, 1 h). The resulting clear solution was heated at reflux (24 h). The new solution was allowed to cool to room temperature and then was washed with 10% NaOH (2 × 25 mL). Combined aqueous layers were extracted (ether; 3 × 25 mL). Combined organic extracts were washed with H2O (25 mL) and brine (25 mL) and then dried (Na2SO4). The solution was filtered and concentrated. The residual oil was vacuum distilled to give 20 (23.26 2,4-Dimethyl-4-(3-methylphenylthio)-2-pentanol (21). To a 3.0 M solution of MeMgBr (80.5 mL, 0.241 mol) was added dropwise 20 (26.18 g, 0.118 mol) in ether (48 mL). The solution was stirred at room temperature (6 h) and then was poured slowly onto ice. The resulting mixture was neutralized (5% H 2-SO4, pH ∼6.5). The ether layer was separated, and the aqueous layer was extracted (ether; 3 × 50 mL). Organic extracts were combined and dried (Na2SO4). Evaporation of the solvent gave a yellow oil, which vacuum distilled to give 21 (23 2,2,4,4,7-Pentamethylthiochroman (22). To CS 2 (185 mL) was added AlCl3 (52.6 g, 0.39 mol). To the resulting stirred suspension of AlCl3 was added dropwise a solution of 21 (23.5 g, 98.6 mmol) in CS2 (60 mL) at room temperature over 15 min. The resulting suspension was heated at reflux (10 h) with stirring. After cooling to room temperature, the suspension was poured onto ice, and the resulting mixture was stirred (5 min). This mixture was separated (two layers), and the aqueous layer was extracted (ether; 3 × 92 mL). Organic extracts were combined, washed with H 2O (60 mL) and brine (60 mL), and then dried (Na2SO4). Evaporation of the solvent gave an orange oil which vacuum distilled to give 22 (20 2,2,4,4,7-Pentamethyl-6-nitrothiochroman (23). To a solution of thiochroman 22 (15.00 g, 68.1 mmol) in freshly distilled Ac2O (13 mL) at -5°C (ice/salt) was added dropwise a mixture of cold, concentrated HNO3 (4.88 mL) and Ac2O (11.43 mL) over 10 min. After being stirred at -5°C for 90 min, the reaction mixture was poured into a solution of saturated, aqueous NaHCO3 (130 mL), and the resulting emulsion was extracted (H2CCl2, 3 × 78 mL). Combined organic extracts were washed with H2O (42 mL) and brine (42 mL) and were then dried (Na2SO4). Evaporation of the solvent gave a dark brown liquid, which was subjected to flash chromatography [hexanes:EtOAc 2,2,4,4,7-Pentamethyl-6-aminothiochroman (24). A mixture of 23 (5.40 g, 20.3 mmol), iron powder (0.802 g, 14.3 mmol, Sigma-Aldrich Chemical Co.), glacial acetic acid (1.70 g, 28.3 mmol), and absolute EtOH (11 mL) was stirred at reflux (12 h). The reaction was allowed to cool to room temperature and was poured into H 2O (42 mL), and the resulting emulsion was extracted with ether (2 × 38 mL) and HCCl3 (3 × 38 mL). Combined organic extracts were washed with H2O (3 × 38 mL), dried (Na2SO4), and concentrated to give a dark oil. This crude mixture was then dissolved in ether (28 mL), and the resulting solution was extracted with 2 N HCl (2 × 28 mL). The acid solution was neutralized (40% Na2CO3, pH ∼8), and the resulting solution was extracted with ether (2 × 28 mL). The combined extracts were dried (Na2SO4), and the solvent was evaporated to afford amine 24 (2.16 g, 45%) as a tan oil, which crystallized upon standing overnight in the freezer and was recrystallized (hexanes) to give an off white solid: mp 61-63°C
; Growth Inhibition Assays. The OVCAR-3, Caov-3, and SK-OV-3 ovarian carcinoma cell lines were obtained from American Type Culture Collection. The OVCAR-3 cultures were maintained in RPMI media supplemented with 10% fetal bovine serum (FBS). The Caov-3 and SK-OV-3 cultures were maintained in MEM media supplemented with 10% FBS, nonessential amino acids, sodium pyruvate, antibiotics, and antimycotics (complete MEM). A primary culture of a benign ovarian cyst and one of a borderline ovarian tumor were established from specimens obtained from two consenting patients undergoing surgery at the University of Oklahoma Health Sciences Center. The specimens were cut into two fragments, vortexed vigorously, and plated onto 100 mm tissue culture dishes containing complete MEM media. Monolayer cultures that developed were passaged once before cryogenic preservation. All experiments were performed on cultures at passages 3 or 4 in which the majority of cells were epithelial. Fibroblasts began to outgrow the epithelial cells after passage 4. Only lots of FBS with undetectable levels (<10 -8 M) of retinol and retinoic acid isomers were used, as determined by high performance liquid chromatography.
All compounds were dissolved in dimethyl sulfoxide (DMSO) and stored as aliquots of 1000× stock solutions at -70°C. Since the retinoids appeared to be slightly light sensitive, all manipulations involving retinoids were performed under subdued lighting. Each experiment included control cultures that received the same volume of DMSO solvent that was administered in the treatment. The concentration of DMSO in each experiment was always equal to or less than 0.01%, a concentration which was not toxic and which did not induce differentiation.
Cultures were plated in 96-well microtiter plates in volumes of 150 µL at a concentration of 1000 cells/well. The following day, retinoids were added at 4× concentrations in 50 µL of media resulting in final concentrations of 1, 4, 7, and 10 µM of each compound. After 3 days of treatment, the number of living cells was quantitated using the MTS [3-(4,5-dimethylthiazol-2-ol)-5-(3-carboxymethoxyphenyl)-2H-tetrazolium inner salt] assay (Promega Life Science, Madison WI). Metabolically active cells reduce the MTS compound to an aqueous soluble formazan, resulting in an absorbance measurable at 490 nm (Promega Technical Bulletin No.169). A mixture of MTS solution and PMS (phenazine methosulfate) in Dulbecco's phosphate-buffered saline was added to each well. The plate was wrapped with foil and shook at 180 rpm for 5 min on an orbital shaker (Fisher Scienctific, Hanover Park, IL) before incubating at 37°C in 5% CO 2. The plate was removed at various intervals, shook for 5 min, and then read at OD490 on a microtiter plate reader until the readings were in the linear range (0.1-0.6). Each experiment was performed in triplicate, and the three values for each treatment were averaged. To determine the percent growth inhibition, the average OD of the untreated cultures was divided by the average OD of the control cultures treated with solvent alone and multiplied by 100.
Measurements of Reactive Oxygen Species (ROS).
Marker 5-(and 6-)carboxy-2′,7′-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) was obtained from Molecular Probes (Eugene, OR), and 96-well black isoplates were obtained from Perkin-Elmer Life Sciences (Boston, MA). Cells were plated in 96-well black isoplates and treated with the compounds. After the treatment interval, cells underwent serial washes with assay buffer by centrifugation. The assay buffer contained 10 µM glucose, 1 µM calcium chloride, and 2 µM magnesium chloride. Carboxy-H2DCFDA (50 µM) was then added, and the assay for ROS production was initiated as previously described. 26 Fluorescence was measured on a Wallace Victor-2 96-well plate reader (excitation at 485 nm and emission at 538 nm).
Retinoic Acid Receptor Activation. The activation of endogenous receptors in cancer cells was evaluated as previously described. 9b,c,27 Briefly, cultures of SW962 cells and CC-1 cells that had been previously transfected with RARE-RARtk-CAT reporter plasmid were treated with 15a-c, 9-c-RA (positive control), or the same volume of control solvent (DMSO-negative control) at concentrations of 10 -9 , 10 -8 , 10
-7 , 10 -6 , and 10 -5 M for 48 h. Activation of the endogenous receptors in the SW962 and CC-1 cell lines was determined by measuring the level of CAT (chloramphenicol acetyl transferase) protein present in each treated and untreated culture. The ability of these compounds and concentrations to activate each individual retinoic acid receptor (RAR) and retinoic X receptor (RXR) were evaluated as previously cited. 9b,9c
